Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway

<div>Effects of combination treatment with cetuximab and cisplatin on the expressions of proapoptosis proteins and EGFR/AKT signaling pathway proteins. Cells were treated with cetuximab, cisplatin, or the combination treatment of cetuximab and cisplatin for 48 h. The expressions of EGFR, p-EGFR, AKT, p-AKT, Bax, caspase-3, and cleaved caspase-3 in both cells were detected by Western blotting analysis. <i>β</i>-actin was used as a loading control.</div>

Biochemistry Research International

fig4

Figure 4

Figure 4: Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway 

Figure 4 | Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway 